Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

High Prevalence of Cancer Augments the Demand for Cancer Hormone Therapy, Says TMR

Transparency Market Research
Posted on: 13 Sep 16
High Prevalence of Cancer Augments the Demand for Cancer Hormone Therapy, Says TMR

Transparency Market Research discusses the evolution of the cancer hormone therapy market over the past few years in its report. The document discusses the strengths, weaknesses, opportunities, and threats impacting the progress of the global market for the course of coming few years. Furthermore, researchers have also used Porter’s five forces analysis to determine the competitive rivalry in the market and the obstacles the players are likely to face in the near future. The document states that the hormone therapy has become an integral method used for treating various types of cancers across the globe. It deals with the manipulation of endocrine systems by administration of steroid hormones or drugs that restrict the action or result of other hormones that are detrimental to health.

Download free exclusive Brochure of this report:   

The high prevalence of cancer is the obvious reason for the growth of the global cancer hormone therapy market. According to the World Health Organization (WHO), the number of deaths due to cancer by the end of 2022 will be about 14 million per year. The overall market is also gaining an impetus from the growing awareness about hormone therapy amongst physicians and patients. Furthermore, the high acceptance of hormone therapy and the remarkable advancements in the field of the hormone therapy are also propelling their demand.

Hormone therapy is widely being accepted for treating breast and prostate cancer. This therapy can be administered to the patient before or after the primary treatment. Hormone treatment given before the primary treatment is called neoadjuvant treatment, which is designed to kill the cancer cells and aid the primary therapy. On the other hand, the therapy given after the primary treatment is called adjuvant and is known to improve the effect of primary therapy and the eventual cure.

The global cancer hormone therapy is being inhibited by certain side-effects that occur due to the changes in the hormone levels. The commonly seen side-effects of cancer hormone therapy are nausea, vaginal spotting, male breast enlargement, skin rashes, irregular menstrual periods, vaginal dryness, loss of appetite, and impotence among others. The market is also being restricted by the high cost of hormone therapy and the possibility of it not working, which is deterring patients from opting for it.

The leading players operating in the global cancer hormone therapy market are QuatRx Pharmaceuticals, AstraZeneca plc, Merck & co., Novartis International AG, and Pfizer, Inc. among others. The research report includes an assessment of the competitive landscape of the global market and examines the business strategies these players are anticipated to adopt in the near future. The report also includes an assessment of the research and development activities, marketing strategies, and investment plans of these players for the coming few years.

For more information:

Editor's Details

Ankit jain
Transparency Market Research

Last updated on: 13/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.